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ABSTRACT  
4H leukodystrophy (4H) is an autosomal recessive hypomyelinating white matter (WM) 
disorder with neurological, dental and endocrine abnormalities. The aim of this study was to 
develop and validate an MRI scoring system for 4H. A scoring system (0-54) was developed 
to quantify hypomyelination and atrophy of different brain regions. Pons diameter and 
bicaudate ratio were included as measures of cerebral and brainstem atrophy, and reference 
values were determined using controls. Five independent raters completed the scoring system 
in 40 brain MRI scans collected from 36 patients with genetically proven 4H. Interrater 
reliability (IRR) and correlations between MRI scores, age, gross motor function, gender and 
mutated gene were assessed. IRR for total MRI severity was found to be excellent (ICC 0.87, 
95% CI 0.80-0.92), but varied between different items with some (e.g. myelination of the 
cerebellar white matter) showing poor IRR. Atrophy increased with age, in contrast to 
hypomyelination scores. MRI scores (global, hypomyelination, and atrophy scores) 
significantly correlated with clinical handicap (p<0.01 for all three items) and differed 
between the different genotypes. Our 4H MRI scoring system reliably quantifies 
hypomyelination and atrophy in patients with 4H, and MRI scores reflect clinical disease 
severity. 
 
 
KEYWORDS 
4H, leukodystrophy, MRI, hypomyelination 
  
4 
 
INTRODUCTION 
Hypomyelinating disorders constitute a heterogeneous group of different disease entities, 
defined by a permanent and significant lack of central nervous system myelin.1 One of the 
striking features of these conditions is the large variation in severity: some patients have 
virtually no neurological signs and normal cognition, others are severely affected early on and 
wheelchair-bound, usually with less profoundly affected cognitive function. A recent study 
aimed at correlating gross motor function (GMF) with quantitative white matter MRI 
parameters and showed that, in a heterogeneous group of patients with hypomyelination, it is 
mainly the lack of myelin which co-determines motor handicap.2 
Short of quantitative information, it is desirable to grade imaging severity tailored to a single 
hypomyelinating entity by assessing the degree of myelin deficit and atrophy using 
conventional T1- and T2-weighted images, and to correlate these scores with GMF. This 
would be helpful for retrospective studies, as these images are available for most patients, but 
also for routine clinical use, providing useful information for future therapeutic trials. Such 
scoring systems have proven to be a valuable tool for other leukodystrophies such as X-linked 
adrenoleukodystrophy (X-ALD) and metachromatic leukodystrophy (MLD).3,4 Recently, a 
scoring system for Pelizaeus-Merzbacher disease (PMD), the most common hypomyelinating 
disorder, was published, but was not available when we were embarking on this project.5 
We aimed to develop a scoring system for a hypomyelinating disorder, 4H leukodystrophy 
(4H), the second most common hypomyelinating entity6 characterized by hypomyelination, 
hypodontia and hypogonadotropic hypogonadism.7–9 Recessive mutations in either POLR3A, 
POLR3B or POLR1C, encoding subunits of RNA polymerase III and I, cause almost all cases 
with the clinical diagnosis of 4H, with mutations in POLR3B explaining the majority of cases 
in Central and Western Europe and mutations in POLR3C being the least frequent.10–14 
Clinical variation is wide, ranging from mild, even subclinical ataxia to severe motor 
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handicap, and the course is, after a stable phase ranging from 2-3 years to more than 10 years, 
slowly progressive in most. In addition to hypomyelination, MRI findings comprise early 
cerebellar atrophy, especially in cases with mutations in POLR3B, and late, milder 
supratentorial brain atrophy including thinning of the corpus callosum.15 Some white matter 
(WM) structures are better myelinated: the optic radiation, the ventrolateral thalamus, the 
pyramidal tract in the posterior limb of the internal capsule (PLIC), the dentate nucleus and 
the medial lemniscus in the brain stem.16 We present a novel MRI rating scale that reflects 
these findings and determined its interrater reliability and clinical validity. 
 
PATIENTS AND METHODS 
Patient selection 
Brain MRI scans were retrospectively collected from patients with genetically proven 4H 
leukodystrophy from the databases of VU Medical Center in Amsterdam, The Netherlands, 
and Montreal Children’s Hospital in Montreal, Canada. Scans had been performed at different 
scanners (1.5 and 3T) following different protocols at different centers and were included 
when at least axial T2- and T1-weighted images and a sagittal series were available. Only 
patients with MRI scans acquired at age 24 months or later were included because normal 
myelination is not completed before this age.  
Controls 
A total of 86 healthy subjects (45 male, 41 female) with a median age of 6.5 years (range 0-
29) served as a control group. We focused on younger ages as there were no good normal 
values for BCR and brainstem diameter available, in contrast to adults. Reasons for MRI were 
headache, mild epilepsy without focal neurological abnormalities or mild developmental 
delay. All were evaluated by (pediatric) neurologists and radiologists, and no abnormal 
neurological or MRI findings were identified. 
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MRI scoring  
We developed a scoring system to assess hypomyelination and atrophy of different brain 
regions (table 1). Hypomyelination was graded separately on axial T1- and T2-weighted 
images, depending on the signal intensity in relation to the caudate nucelues. Atrophy was 
visually scored for selected structures (cerebellum, corpus callosum; figure 1) and quantified 
using the bicaudate ratio (BCR), defined as the smallest intercaudate distance divided by the 
transverse width of the inner table of the skull at the same level. These distances were 
measured on T2-weighted axial images with the smallest intercaudate distance (figure 2C-D). 
Brainstem atrophy was quantified by measuring maximal anterior-posterior diameter at the 
level of the mid-pons on sagittal images (figure 2E). Overall, patients could receive a score 
between 0-44 for hypomyelination and 0-10 for atrophy, adding up to a total score of 0-54, 
with higher scores corresponding to more severe abnormalities. 
Two neuroradiologists (FB and IH) and three pediatric neurologists (RLP, AV and GB), 
experienced in WM diseases, were asked to individually complete the scoring system for all 
patients. They were blinded to patient identifiers including age (the scores for the two age-
dependent items, BCR and pons diameter, were deduced from the measurements the scorers 
provided). When three or more raters agreed on a score, this score was used for further 
analysis on clinical validity. Items for which less than three raters agreed on a score, were sent 
for a second round of scoring to reach consensus. Interrater reliability (IRR) was assessed for 
all individual MRI scoring items and measurements as well as for overall MRI severity 
scores, separately for the first and second round. Total MRI severity, hypomyelination and 
atrophy scores were analyzed including their association to factors such as age, gender and 
mutated gene. For both pons diameter and BCR, age-related reference ranges were 
determined using scans of controls with normal MRI. 
Correlation to gross motor function  
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Patients were retrospectively classified according to the gross motor function classification 
system (GMFCS)17 based on clinical examination or clinical notes from the year in which the 
MRI study was performed. Retrospective estimation of gross motor function scores was 
previously shown to be reliable.18  
Statistical analysis 
Data were analyzed by SPSS, version 20.0 for Windows (SPSS Inc., Chicago, IL, USA), 
GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA) and R Software (R Foundation 
for statistical computing, Vienna, Austria). For determining reference ranges, normal values 
of BCR and pons diameter were plotted and where appropriate, modelled by a (monotone) 
exponential curve fitted by means of nonlinear least squares. Subsequently, reference ranges 
were determined using population means and standard errors. 
IRR was expressed using the single measure intraclass correlation coefficient (ICC), which 
was analyzed by means of a two-way mixed model based on absolute agreement (for separate 
items) or consistency (for total scores). Cutoffs for ICC were derived from Cicchetti et al. 
1994, with ICC values less than 0.40 being considered poor, values between 0.40 and 0.59 
fair, values between 0.60 and 0.74 good and values between 0.75 and 1.00 excellent.19 
Pearson (r) and Spearman () correlations were computed to determine associations between 
age, GMF and MRI variables including total MRI score, hypomyelination and atrophy scores. 
Subgroup differences for gender, gene mutation and age groups were tested using a general 
linear model, analysis of variance (ANOVA) and Mann-Whitney test and associated p values. 
P values of 0.05 or less were considered significant. 
 
RESULTS 
Patients and controls 
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A total of 40 MRI brain scans (32 on a 1.5T scanner, 8 on a 3T scanner) were collected from 
36 (19 female, 17 male) patients with genetically proven 4H with a median age of 12 years 
(range 2-39 years). Six patients (4 female, 2 male) had mutations in POLR3A, the majority, 
27, in POLR3B (13 female, 14 male) and 3 in POLR1C (2 female, 1 male).  Severity of 
clinical disease varied widely with GMFCS scores ranging from I (n=7) to V (n=2). 
Figure 2 shows the evolution of BCR and pons diameter in controls and patients. There was 
no significant difference between males and females. For grading brainstem and 
supratentorial atrophy in 4H, we pragmatically designed age groups using normal values 
(figure 2; tables 2 A and B).  
In 4H patients, pons diameter was significantly smaller with a mean diameter of 18.38 mm 
(standard deviation (SD) 1.98 mm) versus 20.86 mm (SD 1.89 mm) in controls (p<0.01). 
Similarly, BCR was found to be higher in patients with a mean BCR of 0.094 (SD 0.026) 
versus 0.071 (SD 0.015) in controls (p<0.01). Although this difference was already present in 
younger patients, it further increased with age, indicating progressive volume loss. 
Scoring disagreement and interrater reliability  
In the first round a total of 1080 scores were collected (27 items scored for 40 MRI scans). 
For only 48 (4.4%) scores, less than three raters agreed. In one single patient, the maximum 
number of items with disagreement was 3. After the second assessment of the 48 items with 
diverging scores, only 3 (0.3%) from the total of 1080 scores remained without agreement of 
at least 3 raters. We refrained from imposing a consensus score and accepted that no 
consensus could be reached for these 3 items. 
In the first round, IRR was found to be excellent for all sub-scores, with ICC values for 
consistency of 0.84 (95% CI 0.76-0.90) for hypomyelination, 0.88 (95% CI 0.82-0.93) for 
atrophy and 0.87 (95% CI 0.80-0.92) for total MRI score. Overall, IRR was lower for items 
scored on T1-weighted scans, with some items showing a poor IRR (ICC<0.40). These items 
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included the periventricular frontoparietal border area, parieto-occipital WM (both subcortical 
and periventricular), the anterior limb of the internal capsule (ALIC) and the cerebellar WM. 
In contrast, all items scored on T2-weighted images showed at least a fair IRR (ICC>0.40). 
There was little disagreement on atrophy scores including those scores derived from pons 
diameter and BCR.  
In the second round including the 48 scores with disagreement, results were largely similar. 
One of the difficult items to score was myelination of the cerebellar WM, especially in 
patients with severe cerebellar atrophy. We therefore considered o mitting this region from the 
final score. Analyzing results without this item did not influence overall outcome (not shown), 
therefore we decided not to omit it from the scoring, but, to facilitate future use, to slightly 
modify the system by rating white matter signal of the middle cerebellar peduncles instead.   
MRI severity, hypomyelination and atrophy scores 
Median scores were 31/54 (range 8-45) for total MRI score, 23/44 (range 7-39) for 
hypomyelination and 7/10 (range 0-10) for atrophy. Scores tended to be higher in females 
than in males (median 34 versus 26 respectively, p=0.024). Total MRI scores did not 
significantly increase with age figure 3A). When looking at hypomyelination and atrophy 
scores separately, only atrophy scores were significantly correlated with age (figure 3B-C). 
Global MRI and hypomyelination scores were significantly higher for patients with mutations 
in POLR3A than for patients with mutations in POLR3B while atrophy scores were in the 
same range (figure 4). 
MRI scores and motor disability  
Patients with more limitations in GMF were found to have higher total MRI scores (figure 
3D). However, a large variability of MRI scores was seen with all GMFCS levels, 
interestingly most pronounced in patients with mild disability. A similar distribution was seen 
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for hypomyelination and atrophy scores when analyzed separately, with increasing scores for 
more advanced clinical disease (figure 3E-F). 
MRI scores at follow-up 
Follow-up MRI examinations were available for 4 patients with a time interval ranging from 1 
to 8 years between scans. Atrophy scores either remained stable (n=1) or slightly worsened 
(n=3). Hypomyelination scores, and therefore total MRI severity scores, improved in three of 
them. In those patients who showed improvement of hypomyelination scores, GMFCS 
remained stable (n=2) or worsened slightly (n=1).  
 
DISCUSSION 
The aim of this study was to develop and validate a MRI scoring system for 4H 
leukodystrophy, assessing hypomyelination and atrophy in this hypomyelinating disease. We 
decided to score both hypomyelination and atrophy, as cerebellar atrophy is a known early 
feature of 4H, and as supratentorial atrophy slowly progresses with age. The authors of the 
recently published score for PMD independently also combined atrophy and myelination 
scores. They included FLAIR in addition to T1W and T2W images, but omitted 
measurements to quantify atrophy.5 
IRR was found to be excellent for hypomyelination, atrophy and global MRI severity scores 
when assessed using ICC statistics. Nevertheless, in the first round IRR varied between 
different items of the scoring system with some items showing poor IRR, particularly those 
scored on T1-weighted images. Apparently, these items were more difficult to score or more 
sensitive to rater subjectivity. More precise instructions provided to the raters in the second 
round resulted in better agreement. As some atrophy items were assessed quantitatively 
(BCR20, pons diameter21), scoring of atrophy may be more objective than in the established 
scores for X-ALD or MLD.3,4 BCR was first described as a measure of atrophy in the 1980s 
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and used for a variety of diseases including multiple sclerosis and Alzheimer’s disease.22,23 
Recently, one group used this parameter to measure brain atrophy in PMD.24 In our patients, 
brainstem atrophy sets in much earlier than supratentorial atrophy, possibly at least in part due 
to the early cerebellar atrophy.  
All MRI severity scores – hypomyelination, atrophy and global scores – correlated with gross 
motor function, supporting the hypothesis that not only degree of hypomyelination, but also 
atrophy co-determines handicap. A recent study on MRI changes in PMD reached similar 
conclusions, albeit less pronounced for myelination than for atrophy.5 Also in PMD, another 
group reported correlation of brain atrophy with disability, though without assessing 
myelination.24 In multiple sclerosis, the prototype of acquired white matter disease, brain 
atrophy is at least as important for clinical, especially cognitive impairment as white matter 
lesions.25, 26 Atrophy, in contrast to hypomyelination scores, clearly increased with age, 
suggesting age-dependent neuroaxonal loss rather than loss of myelin, although more long-
term observations are needed to confirm this finding in larger patient groups. Interestingly, in 
4H patients with mild clinical disease, MRI scores differed more widely than in patients with 
more severe disease, confirming our clinical experience.  
In females, MRI scores tended to be higher than in male patients; this might be at least in part 
due to the fact that females were overrepresented in the group of patients with mutations in 
POLR3A. That in the four patients with follow-up scans there were some changes including 
improved myelination scores despite stable or slightly deteriorated GMF, is difficult to 
interpret, due to the small number of follow-up MRIs. Larger studies are needed to study 
evolution of MRI changes and clinical symptoms over time. 
We recently described several patients with atypical forms of 4H, without clear myelin deficit 
and variable neurological signs and symptoms.27 Those patients were not included in this 
study as we focused on typical patients with hypomyelination, but it will be interesting to 
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know whether significantly more myelin in these atypical cases also means less clinical 
handicap once enough cases will become available.    
We were also interested in possible differences between patients with mutations in different 
genes. Although our group consisted mainly of patients with mutations in POLR3B, patients 
with mutated POLR3A had higher mean MRI severity scores than the other two groups, 
consistent with the greater clinical severity with POLR3A mutations shown in our study on a 
large number of patients with 4H leukodystrophy.15 
One might wonder why, in the times of quantitative imaging and volumetry we chose a 
comparably simple approach for this scoring system. It has several benefits: the sequences we 
used are part of standard protocols and therefore usually available, they can be compared 
among diverse scanners (with their slightly different protocols), and there is no need for 
specific control groups. Quantitative methods are more objective than a rater-dependent 
approach and often depend on specific scanners, making it laborious or even impossible to 
compare results between different centers or with changing MRI systems in even the same 
center. A robust, simple method as ours may be used in multicenter studies and also can make 
use of MRIs collected during a longer period, essential for a rare disease as 4H 
leukodystrophy. These advantages are at the same time the limitations of this study: the use of 
different scanners with different field strengths and protocols and the retrospective setup may 
have affected results. That we did find correlations between MRI changes and clinical 
severity despite these odds and that these correlations are comparable to other recent MRI 
studies on PMD, is encouraging and strengthens our interpretation.      
In conclusion, this study shows that the proposed MRI scoring system reliably quantifies 
hypomyelination and atrophy, both correlating with clinical disease severity, in patients with 
4H leukodystrophy. It is easy to apply, even retrospectively, might serve as a useful 
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biomarker for future studies and can be used, with small adaptations, for other 
hypomyelinating disorders.  
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FIGURE LEGENDS 
Figure 1: Corpus callosum and cerebellar atrophy. 
In (A), a normal corpus callosum is shown with a score of 0 points, in (B) a slightly thinned 
corpus callosum (score 1 point) and in (C), a severey thinned corpus callosum (score 2 
points). (D) depicts a normal cerebellar hemisphere (0 points), (E) a mildly atrophic cerebellar 
hemisphere (1 point) and (F) a severely atrophic cerebellar hemisphere (2 points). (G) 
displays a normal cerebellar vermis (0 points), (H) a mildly atrophic one (1 point) and (I) a 
severely atrophic cerebellar vermis (2 points).   
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Figure 2: Bicaudate ratio and pons diameter in controls and patients 
(A) shows controls (black dots) with the (monotone) exponential curve (red) fitting best for 
this parameter (BCR = b0 + b1*exp(-month / ϑ) with  b0 = 6.475216e-02, b1 = 1.052684e-03 
and ϑ = -1.149132e+02; striped line: -1 standard deviation, dotted line: -2 standard deviations) 
and patients. Mainly patients > 16 years show supratentorial volume loss. (B) displays 
evolution of pons diameter in controls (black dots), again with the (monotone) exponential 
curve (red) fitting best for this parameter (pons diameter = b0 + b1*exp(-month / ϑ) with  b0 
= 23.903129, b1 = -6.064256 and ϑ = 132.567216; striped line: -1 standard deviation, dotted 
line: -2 standard deviations), and patients, showing early brainstem atrophy in 4H patients. 
(C) and (D) are examples of measuring BCR in two patients, one with a normal result of 
0.079 at age 13 years (C), one with clear atrophy and a BCR of 0.155 at age 33 years (D). (E) 
shows a sagittal T2W image of a young patient with normal pons diameter of 19.5 mm at age 
2 years. Red diamonds: patients with mutations in POLR3A, blue triangles: patients with 
mutations in POLR3B, green squares: patients with mutations in POLR1C. 
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Figure 3: MRI scores in relation to age and gross motor function. 
Global MRI score (A) and hypomyelination score (B) do not show significant correlation with 
age, whereas atrophy is significantly correlated with age (C). All three scores significantly 
correlate with gross motor function (D-F). Red diamonds: patients with mutations in 
POLR3A, blue triangles: patients with mutations in POLR3B, green squares: patients with 
mutations in POLR1C.  
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Figure 4: MRI scores in relation to mutated gene  
Score results (mean and standard error of the mean) depicted for the three patient groups 
(patients with mutations in POLR3A, POLR3B and POLR1C, respectively). Global (A) and 
hypomyelination (B) scores significantly differ between patients with POLR3A and POLR3B 
mutations (Mann-Whitney test, * p < 0.05; *** p < 0.001). Atrophy scores do not show 
significant differences (C). We did not include the three patients with POLR1C mutations in 
this analysis as this latter group was very small. Red diamonds: patients with mutations in 
POLR3A, blue triangles: patients with mutations in POLR3B, green squares: patients with 
mutations in POLR1C. 
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TABLES 
Table 1: Brain MRI scoring system for 4H leukodystrophy 
 
Brain area – white matter T1W  T2W T1W + T2W 
Frontal white matter    
 Subcortical 0-2 0-2 0-4 
 Periventricular 0-2 0-2 0-4 
Frontoparietal border area     
 Subcortical 0-2 0-2 0-4 
 Periventricular 0-2 0-2 0-4 
Parieto-occipital white matter    
 Subcortical 0-2 0-2 0-4 
 Periventricular 0-2 0-2 0-4 
Internal capsule    
 ALIC 0-2 0-2 0-4 
 Pyramidal tracts in PLIC 0-2 0-2 0-4 
Corpus callosum    
 Genu 0-2 0-2 0-4 
 Splenium 0-2 0-2 0-4 
Middle cerebellar peduncles* 0-2 0-2 0-4 
Total white matter score 0-22 0-22 0-44 
 
Brain area - atrophy 
   
Supratentorial (bicaudate ratio)   0-2 
Corpus callosum   0-2 
Brainstem (pons diameter)   0-2 
Cerebellar vermis   0-2 
Cerebellar hemispheres   0-2 
Atrophy score   0-10 
 
Total score (white matter and atrophy) 
   
0-54 
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White matter scores: T1W images: 0 = hyperintense, 1 = isointense, 2 = hypointense in 
relation to caudate nucleus. T2W images: 0 = hypointense, 1 = isointense, 2 = hyperintense in 
relation to caudate nucleus. 
Atrophy scores: bicaudate ratio and pons diameter see tables 2 A-B. Corpus callosum: 0 = 
normal, 1 = slightly thinned, 2 = severely thinned. Cerebellar vermis and cerebellar 
hemispheres: 0 = normal, 1 = mild atrophy with slightly enlarged interfolial spaces, 2 = severe 
atrophy with clearly enlarged interfolial spaces. 
*middle cerebellar peduncles: this item replaces cerebellar white matter in the original scoring 
system. 
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Table 2A: Scoring brainstem atrophy based on pons diameter 
 
Score 
2-3  
years 
4-5  
years 
6-7  
years 
8-9  
years 
10-12 
years 
13-14 
years 
15-19 
years 
20-22 
years 
> 23 
years 
0 ≥18 ≥19 ≥19 ≥20 ≥20 ≥21 ≥21 ≥22 ≥22 
1 
17.99-
16.01 
18.99-
16.01 
18.99-
17.01 
19.99-
17.01 
19.99-
18.01 
20.99-
18.01 
20.99-
19.01 
21.99-
19.01 
21.99-
20.01 
2 ≤16 ≤16 ≤17  ≤17 ≤18  ≤18   ≤19 ≤19 ≤20 
 Pons diameter (mm) 
 
 
Table 2B: Scoring supratentorial atrophy based on bicaudate ratio 
 
Score 
2-9  
years 
10-18 
years 
19-23 
years 
> 24 years 
 
0 <0.085 <0.090 <0.095 <0.100 
1 0.085-0.100 0.090-0.105 0.095-0.110 0.100-0.115 
2 >0.100 >0.105 >0.110 >0.115 
 BCR 
 
 
